As a wave of novel viral vector-based therapies enter pipelines enabling greater payload efficiency then seen before, the spotlight it on ensuring characterization and analytical development to enable economically viable capsid production at scale.

With it crucial analytical method development keeps to pace with pipeline progress, in this new era biopharma teams are faced with the urgent need to gain clarity across regulatory expectations and fit-for-purpose analytical technologies to define robust CQA’s. With the end goal to leverage analytics for faster process development read-out and optimization, there’s heightened awareness of the importance of characterizing viral vectors to demonstrate confidence of product quality for patient safety.

To address key bottlenecks and provide learnings across industry’s priorities, the Viral Vector Characterization & Analytical Development Summit took place with updates from AAV, LV & RV strategies for cell, gene & vaccine pipelines, to inform thinking for the best analytical development path forward with precision, accuracy, quality and efficacy optimized throughout.

Attendees joined peers at an exciting time for viral-vector based therapies, to execute analytical assays for enabling smooth transitions from bench to bedside.